News Releases

August 31, 2020
Unum Therapeutics Transfers BOXR Cell-Based Therapy Technology to SOTIO
Transaction focused on the BOXR technology including lead program BOXR1030   Company fully focused on the development of small molecule precision kinase inhibitors to treat a range of genetically driven diseases   Peter Harwin appointed as Board Chair CAMBRIDGE, Mass. , Aug.
August 11, 2020
Unum Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Updates
Completed acquisition of Kiq, including lead clinical-stage compound PLX9486, a potent and selective KIT D816V inhibitor   Company positioned to advance best-in-class precision kinase inhibitors   Advancing clinical trials in Systemic Mastocytosis and Gastrointestinal Stromal Tumors ('GIST')
July 6, 2020
Unum Therapeutics Inc. Announces Acquisition of Kiq LLC
Acquisition includes lead clinical-stage compound PLX9486, a potent and selective KIT D816V inhibitor   Company positioned to advance best-in-class precision kinase inhibitors   Proceeds of $104.4 million to be used to advance clinical testing in mastocytosis and GIST   Conference call today at
May 11, 2020
Unum Therapeutics Reports First Quarter Financial Results and Provides Corporate Updates
CAMBRIDGE, Mass. , May 11, 2020 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a biopharmaceutical company focused on developing curative cell therapies for solid tumors, today announced financial results for the first quarter ended March 31, 2020 , and provided corporate updates.
March 26, 2020
Unum Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Updates
CAMBRIDGE, Mass. , March 26, 2020 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a biopharmaceutical company focused on developing curative cell therapies for solid tumors, today announced financial results for the fourth quarter and full year ended December 31, 2019 , and provided
March 20, 2020
Unum Therapeutics Announces Common Stock Purchase Agreement for up to $25 Million with Lincoln Park Capital
CAMBRIDGE, Mass. , March 20, 2020 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a biopharmaceutical company focused on developing curative cell therapies for solid tumors, today announced it has entered into a common stock purchase agreement for up to $25 million with Lincoln Park
March 2, 2020
Unum Therapeutics Implements Strategic Restructuring to Prioritize Efforts on BOXR1030 for the Treatment of Solid Tumor Cancers
BOXR1030 is a GPC3-targeted CAR T cell incorporating the novel GOT2 transgene designed to improve T cell function in the solid tumor microenvironment by enhancing T cell metabolism Investigational new drug (IND)-enabling studies are underway for BOXR1030 with plans to submit an application to the
January 29, 2020
Unum Therapeutics Provides Updates to its Phase 1 Trial of ACTR707 for HER2+ Solid Tumor Cancers
-Cohort 1 enrollment is complete with no dose-limiting toxicities observed- -Cohort 2 patient screening underway- -Safety and efficacy data from multiple dose cohorts expected during 2020- CAMBRIDGE, Mass. , Jan. 29, 2020 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc.
Displaying 11 - 18 of 18
The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Unum disavows any obligation to update the information contained in such press releases after the date of their issuance.